zoner newron



Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain with special consideration for rare diseases. Its organization has recently been strengthen by the establishment of the US affiliate, Newron Pharmaceuticals US, Inc., based in Morristown, NJ.



The pipeline is well balanced:

Safinamide in Parkinson’s Disease

•         Internationally licensed to Zambon for Europe, the USA (where Zambon has partnered the product to US WorldMeds) and other markets with the exclusion of Japan and other key Asian markets licensed to Meiji Seika

•         Marketing Authorization received from the EU Commission in February 2015. The approval covers the indication “safinamide as add-on therapy to levodopa alone or in combination with other Parkinson’s disease treatments” in mid-to late stage Parkinson’s disease patients

•         Under regulatory review in the USA

•         Under clinical development in Japan

Orphan drug development projects

•         Sarizotan in Rett Syndrome

•         Ralfinamide for rare neuropathic pain conditions

Evenamide (formerly known as NW-3509) as first add-on therapy in schizophrenia

Personnel consists of 25 Employees in Bresso (Italy) and Morristown, NJ (USA)

The company is listed at SIX Swiss Exchange with the trading symbol NWRN





Personnel consists of 23 Employees in Bresso (Italy), Basel (Switzerland) and Stockholm (Sweden).

The company is listed at SIX Swiss Exchange with the trading symbol NWRN.



newron imagine